» Products and Services » In-Out Licensing: Product valuation

Anaxomics gives assistance to biopharma and pharmaceutical companies in defining their in-/out-licensing strategy and maximizing the value of their products, and technologies.

  1. Current Situation and Market Analysis
  2. Efficacy Analysis
  3. Safety Analysis
  4. Strategic Differentiation
  5. Integrated Product Assessment

clear_strategyIn and out-licensing activities are excellent opportunities for companies that want to quickly expand their portfolio or obtain an immediate return on investment, respectively. However, it is crucial to gain a deep knowledge on the market and the clinical profile of the drugs in order to de-risk scientific decisions during the due-diligence process.

Anaxomics provides a rationale for in/out-licensing decisions based on their expected clinical performance and a comprehensive cross-examination of the competitive landscape. To do so, we offer a novel approach to due diligence that combines cutting-edge Systems Biology with long-term expertise in drug development.

Besides the mechanistic and predictive analysis of the therapeutic performance of your products, we offer a full range of strategic knowledge to add value to your assets and differentiate your new developments.

Current situation and market analysis – In-depth market analysis to identify potential competitors of your compounds with the aim of highlighting their main strenghts during the out-licensing process. When considering the acquisition or the in-licensing of new strategic assets, we conduct a careful examination of the competitor landscape in that therapeutic area. [+]

Efficacy analysis – A comparative efficacy assessment that highlights the strong points of your products and identifies the best drugs available for licensing. To help you in the out-licensing process, we suggest you efficacy-related key factors and potential indications that differentiate your compound from others. [+]

Safety analysis – A comparative safety assessment that highlights the values of your molecules and identifies the safest drugs available for licensing. To help you in the out-licensing process, we suggest you safety-related and life-quality key factors that differentiate your compound from others. [+]

Strategic differentiation – An extensive evaluation of your products’ strengths in the competitive landscape in order to raise its value in the out-licensing process. [+]

Integrated product assessment: A complete evaluation of your product or drugs available for in-licensing, encompassing the services listed above. A unique experience that combines the best systems biology can offer with in-depth market analysis and strategic differentiation advice.

Our value proposition at a glance

The integration of cutting-edge systems biology with the support of qualified experts in other disciplines ensures a unique approach to the due-diligence process.

  • Providing the best strategies to exploit your pipeline
  • Highlighting the values of the molecules and identifying their strengths vs. competitors
  • Predicting rate of success in terms of safety or efficacy and providing a complete understanding of the therapeutic performance and the mechanism of action of a drug
  • Identifying the best products for in-licensing
Contact Us